P-Glycoproteins
"P-Glycoproteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A subfamily of transmembrane proteins from the superfamily of ATP-BINDING CASSETTE TRANSPORTERS that are closely related in sequence to P-GLYCOPROTEIN. When overexpressed, they function as ATP-dependent efflux pumps able to extrude lipophilic drugs, especially ANTINEOPLASTIC AGENTS, from cells causing multidrug resistance (DRUG RESISTANCE, MULTIPLE). Although P-Glycoproteins share functional similarities to MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS they are two distinct subclasses of ATP-BINDING CASSETTE TRANSPORTERS, and have little sequence homology.
Descriptor ID |
D018435
|
MeSH Number(s) |
D12.776.157.530.100.652 D12.776.157.530.450.074.500.500.875 D12.776.395.550.020.610 D12.776.543.550.192.610 D12.776.543.585.100.610 D12.776.543.585.450.074.500.500.875
|
Concept/Terms |
P-Glycoproteins- P-Glycoproteins
- P Glycoproteins
- ATP-Binding Cassette, Sub-Family B Proteins
- ATP Binding Cassette, Sub Family B Proteins
- Multidrug Resistance Proteins
|
Below are MeSH descriptors whose meaning is more general than "P-Glycoproteins".
Below are MeSH descriptors whose meaning is more specific than "P-Glycoproteins".
This graph shows the total number of publications written about "P-Glycoproteins" by people in this website by year, and whether "P-Glycoproteins" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
2010 | 0 | 1 | 1 | 2012 | 0 | 2 | 2 | 2013 | 0 | 1 | 1 | 2014 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "P-Glycoproteins" by people in Profiles.
-
Joy MS, Roberts BV, Wang J, Hu Y, Hogan SL, Falk RJ. A pilot study of leukocyte expression patterns for drug metabolizing enzyme and transporter transcripts in autoimmune glomerulonephritis. Int J Clin Pharmacol Ther. 2014 Apr; 52(4):303-13.
-
Frelinger AL, Bhatt DL, Lee RD, Mulford DJ, Wu J, Nudurupati S, Nigam A, Lampa M, Brooks JK, Barnard MR, Michelson AD. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function. J Am Coll Cardiol. 2013 Feb 26; 61(8):872-9.
-
Singer S, Zhao R, Barsotti AM, Ouwehand A, Fazollahi M, Coutavas E, Breuhahn K, Neumann O, Longerich T, Pusterla T, Powers MA, Giles KM, Leedman PJ, Hess J, Grunwald D, Bussemaker HJ, Singer RH, Schirmacher P, Prives C. Nuclear pore component Nup98 is a potential tumor suppressor and regulates posttranscriptional expression of select p53 target genes. Mol Cell. 2012 Dec 14; 48(5):799-810.
-
Joy MS, La M, Wang J, Bridges AS, Hu Y, Hogan SL, Frye RF, Blaisdell J, Goldstein JA, Dooley MA, Brouwer KL, Falk RJ. Cyclophosphamide and 4-hydroxycyclophosphamide pharmacokinetics in patients with glomerulonephritis secondary to lupus and small vessel vasculitis. Br J Clin Pharmacol. 2012 Sep; 74(3):445-55.
-
Joy MS, Boyette T, Hu Y, Wang J, La M, Hogan SL, Stewart PW, Falk RJ, Dooley MA, Smith PC. Effects of uridine diphosphate glucuronosyltransferase 2B7 and 1A7 pharmacogenomics and patient clinical parameters on steady-state mycophenolic acid pharmacokinetics in glomerulonephritis. Eur J Clin Pharmacol. 2010 Nov; 66(11):1119-30.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|